20
First-in-human phase 1 trial of the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of WSD0922-Fu: Initial report from dose escalation cohort. Sani H. Kizilbash, Kurt Jaeckle, Maciej Mrugala, Jacob Allred, Joel Reid, Anita Lammers, Wei Zhong, Konstantinos Leventakos, Aaron Mansfield, Mohamed Shanshal, Wen Wee Ma, Joon Uhm, Jian L. Campian, Michael Ruff, Ugur Sener, Evanthia Galanis, Terence Burns, Caterina Giannini, Jann Sarkaria, Alex A. Adjei. ASCO 2023 Abstract
Found on CV